Demonstrates the impact and synergy of BioGenerator’s pre-investment programs to de-risk and build new companies capable of advancing rapidly to venture capital investment. SentiAR has progressed quickly from initial formation to a $1.1M seed round.
SentiAR is developing technology to revolutionize the operating room with augmented reality software designed to improve visualization in cardiac surgeries and other interventional procedures. SentiAR is based on technology developed at Washington University by Drs. Jennifer Silva, Pediatric Cardiologist, and Jonathan Silva, Assistant Professor of BioMedical Engineering. Experienced startup executive Jim Howard serves as CEO. BioGenerator supported the founders of SentiAR with its non-dilutive grants and pre-company mentoring, and then co-led the company’s initial financing.
BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business SBIR/STTR programs to refine the business plan, de-risk, and seek additional funding. BioGenerator Grants paid 3rd party expertise to define regulatory and IP strategies and a commercialization plan. BioGenerator Senior Director Harry Arader and EIR David Christenson were instrumental in early activities such as refining strategy and assembling a management team.
Following the significant progress in the pre-investment phase, BioGenerator co-led an initial $1.1M seed financing for SentiAR in 2017. BioGenerator invested $800K total in the Seed and Series A rounds and Senior Vice President Charlie Bolten served on the company’s Board of Directors.